40 related articles for article (PubMed ID: 6162806)
1. Observations on the EB virus envelope and virus-determined membrane antigen (MA) polypeptides.
North JR; Morgan AJ; Epstein MA
Int J Cancer; 1980 Aug; 26(2):231-40. PubMed ID: 6162806
[TBL] [Abstract][Full Text] [Related]
2. Four Decades of Prophylactic EBV Vaccine Research: A Systematic Review and Historical Perspective.
Escalante GM; Mutsvunguma LZ; Muniraju M; Rodriguez E; Ogembo JG
Front Immunol; 2022; 13():867918. PubMed ID: 35493498
[TBL] [Abstract][Full Text] [Related]
3. Vaccine Development for Epstein-Barr Virus.
Cohen JI
Adv Exp Med Biol; 2018; 1045():477-493. PubMed ID: 29896681
[TBL] [Abstract][Full Text] [Related]
4. Kinetics of Epstein-Barr Virus (EBV) Neutralizing and Virus-Specific Antibodies after Primary Infection with EBV.
Bu W; Hayes GM; Liu H; Gemmell L; Schmeling DO; Radecki P; Aguilar F; Burbelo PD; Woo J; Balfour HH; Cohen JI
Clin Vaccine Immunol; 2016 Apr; 23(4):363-9. PubMed ID: 26888186
[TBL] [Abstract][Full Text] [Related]
5. Epstein-barr virus vaccines.
Cohen JI
Clin Transl Immunology; 2015 Jan; 4(1):e32. PubMed ID: 25671130
[TBL] [Abstract][Full Text] [Related]
6. Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge.
Sashihara J; Hoshino Y; Bowman JJ; Krogmann T; Burbelo PD; Coffield VM; Kamrud K; Cohen JI
PLoS Pathog; 2011 Oct; 7(10):e1002308. PubMed ID: 22028652
[TBL] [Abstract][Full Text] [Related]
7. Antibodies to lytic infection proteins in lymphocryptovirus-infected rhesus macaques: a model for humoral immune responses to epstein-barr virus infection.
Orlova N; Fogg MH; Carville A; Wang F
Clin Vaccine Immunol; 2011 Sep; 18(9):1427-34. PubMed ID: 21734064
[TBL] [Abstract][Full Text] [Related]
8. Identification of an Epstein-Barr virus nuclear antigen by fluoroimmunoelectrophoresis and radioimmunoelectrophoresis.
Strnad BC; Schuster TC; Hopkins RF; Neubauer RH; Rabin H
J Virol; 1981 Jun; 38(3):996-1004. PubMed ID: 7017165
[TBL] [Abstract][Full Text] [Related]
9. Clinical consequences of Epstein-Barr virus infection and possible control by an anti-viral vaccine.
Epstein MA; Morgan AJ
Clin Exp Immunol; 1983 Aug; 53(2):257-71. PubMed ID: 6309441
[No Abstract] [Full Text] [Related]
10. Synthesis and processing of the three major envelope glycoproteins of Epstein-Barr virus.
Edson CM; Thorley-Lawson DA
J Virol; 1983 May; 46(2):547-56. PubMed ID: 6302318
[TBL] [Abstract][Full Text] [Related]
11. Purified Epstein-Barr virus Mr 340,000 glycoprotein induces potent virus-neutralizing antibodies when incorporated in liposomes.
North JR; Morgan AJ; Thompson JL; Epstein MA
Proc Natl Acad Sci U S A; 1982 Dec; 79(23):7504-8. PubMed ID: 6296836
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus induced proteins V: comparison of EBV-specific polypeptides from different virus strains.
Georg-Fries B; Mueller-Lantzsch N
Med Microbiol Immunol; 1982; 171(1):11-21. PubMed ID: 6289060
[TBL] [Abstract][Full Text] [Related]
13. Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo.
Thorley-Lawson DA; Poodry CA
J Virol; 1982 Aug; 43(2):730-6. PubMed ID: 6287039
[TBL] [Abstract][Full Text] [Related]
14. Membrane antigen on Epstein--Barr virus-infected human B cells recognized by a monoclonal antibody.
Slovin SF; Frisman DM; Tsoukas CD; Royston I; Baird SM; Wormsley SB; Carson DA; Vaughan JH
Proc Natl Acad Sci U S A; 1982 Apr; 79(8):2649-53. PubMed ID: 6283539
[TBL] [Abstract][Full Text] [Related]
15. Neutralization of lymphocyte immortalization by different strains of Epstein-Barr virus with a murine monoclonal antibody.
Miller G; Heston L; Hoffman G
Infect Immun; 1982 Sep; 37(3):1028-31. PubMed ID: 6182100
[TBL] [Abstract][Full Text] [Related]
16. Production and characterization of monoclonal antibodies against the Epstein-Barr virus membrane antigen.
Strnad BC; Schuster T; Klein R; Hopkins RF; Witmer T; Neubauer RH; Rabin H
J Virol; 1982 Jan; 41(1):258-64. PubMed ID: 6177865
[TBL] [Abstract][Full Text] [Related]
17. Identification of Epstein-Barr virus strain differences with monoclonal antibody to a membrane glycoprotein.
Qualtiere LF; Chase R; Vroman B; Pearson GR
Proc Natl Acad Sci U S A; 1982 Jan; 79(2):616-20. PubMed ID: 6176998
[TBL] [Abstract][Full Text] [Related]
18. Expression of the Epstein-Barr virus gp350/220 gene in rodent and primate cells.
Whang Y; Silberklang M; Morgan A; Munshi S; Lenny AB; Ellis RW; Kieff E
J Virol; 1987 Jun; 61(6):1796-807. PubMed ID: 3033311
[TBL] [Abstract][Full Text] [Related]
19. Recombinant vaccinia virus induces neutralising antibodies in rabbits against Epstein-Barr virus membrane antigen gp340.
Mackett M; Arrand JR
EMBO J; 1985 Dec; 4(12):3229-34. PubMed ID: 3004944
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Epstein-Barr virus (EBV) release from P3HR-1 and B95-8 cell lines by monoclonal antibodies to EBV membrane antigen gp350/220.
Sairenji T; Bertoni G; Medveczky MM; Medveczky PG; Nguyen QV; Humphreys RE
J Virol; 1988 Aug; 62(8):2614-21. PubMed ID: 2839689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
